Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diet showdown: mediterranean vs DASH for fatty liver

NCT ID NCT07622680

Disease control Sponsor: University of Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether Mediterranean or DASH diets improve liver function in people with nonalcoholic fatty liver disease (NAFLD). 75 adults with mild to moderate liver enzyme elevations were split into three groups: one following general dietary guidelines, one on a Mediterranean diet, and one on a DASH diet. Researchers measured body mass index and liver enzymes before and after the diet period to see which approach worked best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mediterranean diet and DASH diet
What this could lead to
If successful, this could show that specific diets like Mediterranean or DASH help manage NAFLD and improve liver health without medication.
What could go wrong
This is a small, completed study with 75 participants, so results may not apply to everyone. Dietary changes can be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Nov 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (25-70 years) of both genders with BMI (above 25 kg/m2). * Fatty liver patients with mild to moderate values of Alanine Transaminase (ALT) level range from mild to moderate (30-100U/L) * Fatty liver patients having Aspartate Aminotransferase (AST) level range from mild to moderate (200-600 IU/L). * Fatty liver patients having Gamma-Glutamyl Transferase (GGT level range from mild to moderate(120-300 U/L) were included. Exclusion Criteria: * Lactating and pregnant women were not included. * Patients who are using any kind of medicine. * Adults suffering from critical health conditions, including cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hep A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis A virus infection metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hep A NAFLD - nonalcoholic fatty liver disease

Contacts and locations

Locations

  • University of Lahore

    Lahore, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.